Last reviewed · How we verify
Dolutegravir Pediatric Granules
Dolutegravir Pediatric Granules is a Small molecule drug developed by ViiV Healthcare. It is currently in Phase 1 development.
At a glance
| Generic name | Dolutegravir Pediatric Granules |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (PHASE1)
- Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir Pediatric Granules CI brief — competitive landscape report
- Dolutegravir Pediatric Granules updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI
Frequently asked questions about Dolutegravir Pediatric Granules
What is Dolutegravir Pediatric Granules?
Dolutegravir Pediatric Granules is a Small molecule drug developed by ViiV Healthcare.
Who makes Dolutegravir Pediatric Granules?
Dolutegravir Pediatric Granules is developed by ViiV Healthcare (see full ViiV Healthcare pipeline at /company/viiv-healthcare).
What development phase is Dolutegravir Pediatric Granules in?
Dolutegravir Pediatric Granules is in Phase 1.
Related
- Manufacturer: ViiV Healthcare — full pipeline
- Compare: Dolutegravir Pediatric Granules vs similar drugs
- Pricing: Dolutegravir Pediatric Granules cost, discount & access